The p38 mitogen-activated protein kinase (MAPK) pathway regulates multiple physiologic and pathologic processes, including cancer development. PRAK, a p38 substrate protein kinase, has previously been implicated in the suppression of skin carcinogenesis. In the current study, we show that PRAK deletion accelerates hematopoietic cancer development in a mouse model harboring an oncogenic ras allele, Em-N-Ras G12D
Introduction
The p38 mitogen-activated protein kinase (MAPK) was initially identified as a mediator of inflammation and stress responses (1) (2) (3) (4) . Recent studies have revealed a novel function of the p38 pathway in tumor-suppressing cellular responses such as oncogene-induced senescence, cell contact inhibition, and DNA damage responses (5) . These findings suggest that p38 has a tumor-suppressing function. Indeed, tissue-specific deletion of p38a promotes the development of chemical-induced liver cancer and K-ras G12V -induced lung cancer in mice (6, 7) . Moreover, deletion of Wip1, a p38 phosphatase frequently amplified in human breast tumors, leads to p38 activation and reduced erbB2-and ras-mediated mammary tumorigenesis in mice (8, 9) .
Like other MAPK pathways, the functions of p38 are mediated by its downstream substrates. Numerous p38 substrates, including serine/threonine protein kinases, transcription factors, and cell-cycle regulators, have been identified that mediate various p38 functions (10) . The p38 downstream kinase substrates include MAPK-activated kinases 2 (MK2) and 3 (MK3), MAPK-interacting protein kinase 1 (MNK1), p38-regulated/activated kinase (PRAK), mitogen-and stress-activated protein kinases-1 (MSK1) and -2 (MSK2), and casein kinase 2 (CK2). Upon phosphorylation by p38, these Ser/Thr protein kinases activate substrates such as heat shock proteins, transcription factors, translation initiation factors, and proteins that regulate mRNA stability. In a previous study, we showed that the ability of p38 to mediate oncogene-induced senescence and tumor suppression relies, at least in part, on PRAK. Replicative senescence is a stable proliferative arrest associated with the exhaustion of replicative potential as a result of telomere erosion during cell divisions (11) . Telomere length-independent, senescence-like proliferative arrest can also be induced in young cells by activated oncogenes such as ras (12) . This second type of arrest state is thus operatively termed as oncogene-induced premature senescence. Like apoptosis, oncogene-induced senescence serves as an antitumorigenic defense mechanism (13) (14) (15) (16) . Our studies revealed that PRAK is essential for ras-induced senescence and that PRAK deficiency disrupts oncogene-induced senescence and enhances 7,12-dimethylbenz(a)anthracene (DMBA)-induced skin carcinogenesis (17) .
While our previous results indicate that PRAK suppresses skin carcinogenesis (17) , it is unclear whether the tumorsuppressing activity of PRAK also operates in other types of cancers. To this end, the consequence of PRAK inactivation was analyzed in the current study using an N-ras colony formation induced by activated ras in primary splenocytes. Further studies indicate that enhanced hematopoietic tumorigenesis by PRAK deficiency is accompanied by hyperinduction of the c-jun-NH 2 -kinase (JNK) pathway and downregulation of a subset of senescence markers, and that inhibition of JNK activity attenuates the hyperproliferation induced by oncogenic ras in hematopoietic cells isolated from PRAK-deficient mice. These findings suggest that PRAK may suppress the development of a broad range of cancers and that in the case of ras-induced hematopoietic cancer, the tumorsuppressing function of PRAK may be attributed to its ability to antagonize the activation of tumor-promoting MAPK pathways by oncogenic ras.
Materials and Methods

Mouse strains
The Em-N-Ras G12D transgenic strain (18) was intercrossed with mice harboring a targeted deletion in the PRAK gene (17) to generate the Em-N-Ras G12D ;PRAK þ/À line (F1), which was then crossed with PRAK þ/À to obtain Em-N-
, Em-N-Ras G12D ;PRAK þ/À , and Em-NRas G12D ;PRAK À/À littermates (F2) for observation of hematopoietic cancer development. The mice were in the BL6/129 background. All the mice carried only one copy of the ras transgene, as the F1 mice were heterozygous for the transgene. Animals were genotyped by allele-specific PCR as described previously. Time to death was defined as the latency between birth and death or a terminal disease stage as indicated by symptoms of severe sickness (lethargy, distress, swollen neck, abdominal bulging). Statistical analysis of Kaplan-Meier survival plots is based on the log-rank (Mantel-Cox) test. After euthanasia of mice with deep anesthesia by CO 2 , tissues were processed for histopathology and subsequent staining with hematoxylin and eosin. Cardiac or tail vein blood was collected into Microvette tubes (Sarstedt) and analyzed by a Hemavet 950 (Drew Scientific).
Immunogenotyping of hematopoietic tumor cells
Organs such as spleen, thymus, and bone marrow were isolated from mice and minced in PBS. The mixture was then filtered through a 70-mm nylon mesh (BD Falcon) to obtain single-cell suspensions. Isolated cells were stained with antibodies against CD11b (R-phycoerythrin-conjugated) and GR-1 (Tricolor-conjugated), or CD3 (R-phycoerythrin-conjugated) and B220 (Tricolor-conjugated; Caltag Laboratories), and analyzed by flow cytometry.
Isolation of primary splenocytes and transduction with recombinant retroviruses ex vivo
Spleen from 8-to 12-week-old nontransgenic mice served as the source for primary splenocyte preparations. Isolated spleens were minced in PBS and filtered through a 70-mm nylon mesh to obtain single-cell suspensions. Erythrocytes were removed by incubating the cell suspension with Ack buffer (0.15 mol/L NH 4 Cl, 1 m mol/L KHCO 3 , and 0.1 m mol/L EDTA). The primary splenocytes were cultivated in a medium containing 45% Iscove minimum essential media, 45% Dulbecco's Modified Eagle's Media (DMEM), 10% FBS, 4 mmol/L L-glutamine, 100 U/mL Pen-strep and 25 mmol/L b-mercaptoethanol (cell culture grade; Life Technologies). The medium was conditioned for 2 to 3 days on gamma-irradiated (20 Gy) NIH3T3 cells before addition to splenocytes.
Two retroviruses encoding short hairpin RNA (shRNA) targeting both JNK1 and JNK2 (shJNK1/2-S1 and -S2) were based on a published article (19) (MSCV-puro-N-Ras G12D ) or corresponding vector controls were packaged in an ecotropic packaging cell line LinX-E as described previously (20, 21) , except that the viruses were produced in the NIH3T3-conditioned splenocyte medium. A total of 1 Â 10 6 freshly isolated splenocytes were mixed with 2 mL of viral supernatant in the presence of 4 mg/mL polybrene, plated onto 6-well plates, and centrifuged at 2,700 rpm for 3 hours. After incubation at 32 C for overnight, cells were subjected to a second round of retroviral infection and then collected by centrifugation and resuspended in NIH3T3-conditioned splenocyte medium. Cells transduced with the retroviruses were selected with 1 mg/mL puromycin or 50 mg/mL hygromycin B.
Analysis of proliferation and colony-forming ability of splenocytes cultured ex vivo
To measure the rate of proliferation, primary splenocytes transduced with oncogenic ras or vector control were seeded onto 12-well plates in triplicates at a density of 1 Â 10 4 to 5 Â 10 4 cells per well in NIH3T3-conditioned splenocyte medium. Cells were harvested 4 to 8 days later and their numbers counted in hemocytometer. To measure colony formation on semisolid medium, 1 Â 10 4 to 5 Â 10 4 of splenocytes were resuspended in the NIH3T3-conditioned splenocyte medium containing 0.3% low melting point agarose and plated onto a solidified bottom layer medium containing 0.5% agarose in 6-well plates, in triplicates. Colonies were photographed after 2 to 3 weeks, stained with 0.02% Giemsa in PBS, and counted. When necessary, 2 mmol/L of SP600125, a JNK-specific inhibitor, or dimethyl sulfoxide (DMSO) was included in the medium.
Immunohistochemical analysis
Frozen tissue samples were sliced into 8-mm sections and stored in À80 C until use. Frozen sections were fixed in 4% buffered paraformaldehyde at 4 C for 10 minutes and incubated with primary antibodies (anti-Ki-67, Thermo Scientific or anti-phospho-JNK-T183/Y185, Cell Signaling) at 4 C for overnight. Signals were detected by Vectastain ABC kit (Vector Laboratories). Samples were counterstained with hematoxylin (Vector Laboratories). Positive cells were quantified under microscope in 20 randomly chosen 40Â fields.
Western blot analysis
Cells were lysed with protein lysis buffer (10 mmol/L Tris HCl, pH 8.0, 140 mmol/L sodium chloride, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) supplemented with 1 mmol/L sodium orthovanadate, 10 mmol/L sodium fluoride, 1 mmol/L b-glycerophosphate, and complete protease inhibitor cocktail (Roche). Cleared cell lysates were mixed with Laemmli sample buffer supplemented with b-mercaptoethanol and boiled for 5 minutes. Equal amount of protein from the cell lysates were fractionated on SDS-PAGE and transferred to the nitrocellulose membrane (BioRad). The antibodies used in this study were purchased from BD Pharmingen (cyclin D1), Cell Signaling (phospho-JNK-T183/Y185, JNK, c-Jun, phospho-AKT-S473, AKT, phospho-ERK-T202/Y204, and ERK2), Santa Cruz (p53, Ras C-20, p19
ARF , and p16 Ink4a -M-156), Sigma (actin), and Stressgen (DcR2). The antibodies against PRAK was described previously (17) . Antibody against mouse p53 phosphorylated at S37 was a gift from Dr. Carol Prives (Columbia University, New York, NY).
Quantitative real-time PCR
RNA was isolated from cells using TRIzol (Life Technologies). cDNA was synthesized with iScript RT Supermix (BioRad) and quantified by real-time PCR using SsoFast SYBR Green Supermix (BioRad) on a CFX96 Real-Time System (BioRad). The primers used for Grap2 were 5 0 -AAGGCCTCTCTCGACATCAA-3 0 and 5 0 -AGATG-GACGTTGTCCGGTAG-3 0 (6).
Results
PRAK deletion facilitates oncogenic ras-induced hematopoietic tumor development
Our previous study indicated that PRAK suppresses skin carcinogenesis induced by an environmental carcinogen DMBA (17) . To evaluate the role of PRAK in hematopoietic tumor formation, we crossed the PRAK-targeted mice with the Em-N-Ras G12D transgenic line harboring an activated NRas G12D transgene under the control of the immunoglobulin (Ig) heavy chain (Em) promoter, which is expressed specifically in hematopoietic cells (18) . Western blot analysis indicated that the ras transgene was expressed at 3-to 4-fold above the endogenous level (Fig. 1A, inset ). These mice develop hematopoietic tumors of myeloid and T lymphoid origins. It was reported that targeted deletion of p53 or Suv39h1, a histone methyltransferase involved in rasinduced senescence, promotes tumor development in these mice (15) .
We monitored cancer development among
, and PRAK À/À littermates carrying the Em-NRas G12D transgene. The PRAK þ/þ mice developed hematopoietic tumors in a time frame consistent with previous reports (15, 18) . The median tumor-free survival of these mice was 236 days. Tumor development was significantly accelerated in the PRAK À/À mice as compared with their PRAK þ/þ littermates, with a median tumor-free survival of 160 days (Fig. 1A) . Tumor development was also enhanced in the PRAK þ/À animals, although only to a moderate level (with a median survival of 205 days). Western blot analysis of the spleens showed that these mice mostly expressed expected levels of PRAK and N-Ras (Fig. 1B) , indicating that PRAK suppresses oncogenic ras-induced hematopoietic tumorigenesis in mice. It is of interest to note that in some of the wild-type tumors, PRAK expression was reduced to similar levels to that in the PRAK þ/À tumors. This finding suggests that at least a subset of wild-type mice developed tumors as a result of spontaneous reduction in PRAK expression. The other PRAK þ/þ tumors retained normal, wild-type PRAK expression, raising a possibility that mutations might have occurred in other components of the PRAK-mediated signaling pathway.
PRAK deletion accelerates formation of hematopoietic tumors of both myeloid and T lymphoid origins
It has been reported that while the Em-N-Ras G12D mice develop hematopoietic tumors of either myeloid or T lymphoid origin, deletion of the p53 or Suv39h1 gene mainly enhances the development of T-cell lymphomas (15) . We thus analyzed the origin of the tumors from PRAK-deficient Em-N-Ras G12D animals, by immunogenotyping the cell types in hematopoietic compartments and analyzing the organs infiltrated by tumors. Consistent with previous reports, about 80% of the tumors developed in wild-type mice were of myeloid origin and 20% of these tumors were of T lymphoid origin. Although heterozygous deletion of p53 increased the incidence of T-cell lymphoma to 45%, PRAK deficiency did not significantly alter the ratio between the 2 types of hematopoietic tumors (Table 1) , despite the shortened disease latency in PRAK þ/À and PRAK À/À animals (Fig. 1A) .
Detailed analysis revealed no difference in tumor characteristics between wild-type and PRAK-deficient mice. The T-cell lymphomas from both wild-type and PRAK-deficient animals were usually associated with enlarged spleen containing increased percentage of T cells (CD3-positive), enlarged lymph nodes and thymus containing almost exclusively T cells, and increased percentage of T cells in bone marrow ( Fig. 2A and Table 2 ). The myeloid malignancies in PRAK
þ/À , and PRAK À/À mice all infiltrated spleen and liver (an organ not involved in T-cell lymphomas; Fig. 2A and B) and displayed increased percentage of CD11b þ GR-1 À myeloid cells in bone marrow and spleen (Table 3 ). In addition, peripheral blood analysis revealed signs of anemia in the myeloid tumor-bearing mice, whereas the white blood cell (including lymphocyte and myeloid cell) counts appeared to be normal (Fig. 2C) .
Therefore, PRAK deficiency accelerates the onset of NRas G12D -induced hematopoietic cancer development without altering the spectrum or characteristics of the tumors. Our results thus suggest that PRAK functions as a tumor suppressor in hematopoietic cells of either myeloid or T lymphoid lineage.
PRAK deficiency confers proliferative advantage in hematopoietic cells transduced with oncogenic ras
To investigate the cellular mechanism underlying the enhanced hematopoietic cancer development in PRAKdeficient mice, we isolated hematopoietic cells from the
, and PRAK À/À littermates that did not carry the N-ras G12D transgene and transduced them with an oncogenic ras allele, H-ras G12V or N-ras G12D (Fig. 3A, inset) . While wild-type cells also attained a higher proliferation rate upon transduction of either of the activated ras alleles as compared with a vector control, ras-induced cell proliferation was much more robust in PRAK-deficient cells than in wild-type cells (Fig. 3A) . We also examined the ability of these cells to grow and form colonies in semisolid media ( Fig. 3B and C) . Cells failed to form any colonies on soft agarose in the absence of oncogenic ras, regardless of the PRAK status (Fig. 3B) . H-ras G12V and N-ras G12D promoted the formation of a number of small colonies in wild-type cells; however, the colony formation by PRAK-deficient cells transduced with activated ras was significantly increased in both size (Fig. 3B) and quantity (Fig. 3C) , as compared with the wild-type cells. These results show that loss of PRAK cooperates with oncogenic ras to induce proliferation and tumorigenesis in hematopoietic cells, suggesting that PRAK, when present in cells, suppresses ras-mediated cell proliferation and oncogenic transformation.
PRAK deficiency abrogates the induction of senescence markers by oncogenic ras
It was reported that activated ras induces senescence in primary splenocytes, which acts as a barrier to lymphoma development (15) . Our previous finding that PRAK suppresses skin carcinogenesis by mediating senescence (17) prompted us to investigate a possible role of PRAK-mediated senescence in hematopoietic cell transformation. However, we failed to detect a growth inhibition by oncogenic ras in either wild-type or PRAK-deficient splenocytes (Fig. 3A) . Instead, ras induced an increase in proliferation in these cell populations. In addition, neither wild-type nor PRAKdeficient splenocytes displayed elevated percentage of cells positive for a senescence marker, senescence-associated b-galactosidase (SA-b-gal), upon transduction of activated ras alleles (data not shown). Nevertheless, oncogenic ras induced accumulation of other senescence markers, including DcR2, p16 INK4a , and p19 ARF (12, 13, 22) , and the induction of these senescence markers by ras was either abolished or greatly reduced in PRAK À/À splenocytes (Fig.  4A) . While the reason why activated ras fails to induced proliferative arrest and SA-b-gal is unclear, our data suggest that a PRAK-dependent senescence response may be, at least partly, responsible, although it may not be the major mechanism, for the tumor-suppressing function of PRAK in hematopoietic cells.
PRAK deficiency enhances oncogenic ras-induced soft agar colony formation in splenocytes through hyperactivation of the JNK pathway Previous studies revealed that p38a negatively regulates the proliferation of several cell types including fetal myeloid cells and that targeted deletion of p38a enhances the proliferation of these cells and promotes cancer development by inducing hyperactivation of the JNK pathway (6) . These reports raise a possibility that PRAK, as a downstream substrate of p38, may participate in the regulation of the JNK pathway and cell proliferation by p38. We thus examined the status of JNK activation in primary splenocytes transduced with oncogenic ras (Fig. 4A) . Indeed, NRas G12D alone induced a moderate increase in the protein levels of phospho-JNK, c-Jun, and a c-Jun downstream target cyclin D1. PRAK deletion alone also caused a weak but consistent induction of these proteins. However, the combination of N-Ras G12D and PRAK deficiency synergistically led to a much higher level of induction of the JNK-c-Jun-cyclin D1 pathway (Fig. 4A) . In contrast, PRAK deletion had no effect on the activating phosphorylation of extracellular signal-regulated kinase (ERK) and AKT induced by oncogenic ras (Fig. 4A) . Furthermore, treatment of the splenocytes with a JNK inhibitor SP600125, or transduction of these cells with shRNAs that effective silenced the expression of both JNK1 and JNK2 (Fig.  4C, inset) , strongly inhibited the induction of soft agar colony formation by oncogenic ras alone or by the combination of oncogenic ras and PRAK deficiency ( Fig. 4B  and C) . Thus, the induction of colony formation by oncogenic ras and the ability of PRAK deficiency to further promote oncogenic ras-induced colony formation both rely on activation of JNK. In addition, PRAK deficiency also enhanced proliferation of Em-N-Ras G12D splenocytes in vitro in a JNK-dependent fashion (Fig. 4D) . Together, these data suggest that PRAK-mediated inhibition of JNK To gain insights into the mechanism for PRAK-mediated JNK inhibition, we examined the expression of a leukocytespecific adaptor protein Grap2. Previous studies show that Grap2 interacts with and enhances the activity of hematopoietic progenitor kinase 1 (HPK1), which in turn activates JNK and promotes proliferation in hematopoietic cells (6, 23) . We found that Grap2 expression was induced by oncogenic ras to a much higher level in PRAK À/À splenocytes than in wild-type cells (Fig. 4E) , suggesting that PRAK inhibits JNK by suppressing the Grap2/HPK1 circuit.
We previously showed that in a skin cancer model, PRAK suppressed carcinogenesis by inducing the tumor-suppressing activity of p53 through phosphorylation of p53 at Ser37 (17) . Oncogenic ras induced total p53 protein levels in both wild-type and PRAK À/À splenocytes (Fig. 4F, top) ; however, when the protein loading was adjusted to achieve comparable amounts of total p53 levels, we failed to detect any increase in the phospho-p53Ser37 level in either wild-type or PRAK À/À splenocytes by Western blot analysis (Fig. 4F,  bottom) . These indicate that the Ras-PRAK-p53Ser37 axis is not operative in splenocytes, suggesting that PRAK deletion accelerates ras-mediated hematopoietic cancer development through a p53Ser37-independent mechanism.
PRAK deficiency leads to hyperactivation of JNK in mice
To determine whether the hyperactivation of JNK mediated by PRAK deficiency occurs in vivo, the activated form of JNK (phospho-JNK-T183/Y185) was analyzed in both hematopoietic tumors and normal spleens by immunohistochemistry. We initially examined hematopoietic tumors isolated at the terminal illness from the spleens of PRAK þ/þ , PRAK (Fig. 5A ). To rule out the possibility that the increased phospho-JNK levels were associated with infiltrated tumor cells, a group of 6-month-old PRAK þ/þ and PRAK À/À littermates with or without the N-ras G12D transgene were examined before any disease symptom was observed in the N-ras G12D animals. Again, although the N-ras G12D transgene induced an increase in the number of phospho-JNK-positive cells in both PRAK þ/þ and PRAK À/À mice as compared with those without the transgene, the induction was much more prominent in the PRAK À/À than in the PRAK þ/þ background (Fig. 5B, top) . Moreover, in the absence of the N-ras G12D transgene, PRAK deficiency also significantly, although moderately, augmented the number of phospho-JNK- Table 3 . Immunogenotyping of cells isolated from indicated organs of wild-type mice or myeloid tumorbearing Em-N-Ras positive cells in spleen (Fig. 5B, top) , even though these mice do not develop cancer without N-ras G12D . This observation thus strongly suggests that the positive effect of PRAK deficiency on JNK activation is not restricted to tumor cells, but occurs also in normal hematopoietic cells and thus serves as the cause, rather than the consequence, of enhanced hematopoietic tumorigenesis. Supporting this notion, the enhancement in JNK activation by PRAK deficiency was observed in the spleens of mice harboring the N-ras G12D transgene in as early as week 9 after birth, a time well before the onset of cancer in any mice, as determined by both immunohistochemical and Western blot analyses (Fig. 5C) . Furthermore, induction of phospho-JNK by the N-ras G12 transgene or PRAK deficiency, and the hyperactivation of JNK by both, strongly correlated with the increases in the number of cells positive for a proliferation marker Ki-67 (Fig. 5B, top and bottom) , suggesting that activation of JNK promotes the proliferation of normal hematopoietic cells as well as tumor cells and contributes to enhanced hematopoietic cancer development.
Discussion
We previously showed that PRAK suppresses DMBAinduced skin carcinogenesis in mice (17) . In the current study, we show that PRAK also inhibits hematopoietic cancer development in mice harboring an activated ras allele, indicating that the tumor-suppressing activity of PRAK operates in multiple tissues. This is consistent with the ubiquitous expression pattern of PRAK in tissues including skin and hematopoietic cells (17, 24) . Analysis of the tumors formed in the Em-N-Ras G12D transgenic mice indicated that PRAK deficiency accelerated the formation of tumors of both lymphoid and myeloid origins, suggesting that PRAK serves as a guardian against tumorigenesis in both hematopoietic lineages. Supporting the role of PRAK in inhibiting hematopoietic cancer development, hematopoietic cells isolated from PRAK-deficient spleens attained a faster proliferation rate and enhanced ability of form colonies on semisolid medium upon transduction of oncogenic ras alleles, as compared with those from wild-type animals.
Enhanced hematopoietic tumorigenesis correlates with hyperactivation of the JNK pathway by PRAK deficiency in both mouse spleen tissues and ex vivo cultivated splenocytes. in vivo, enhanced JNK activation by PRAK deficiency was detected in the spleens of Em-N-Ras G12D transgenic animals from well before the disease onset all the way to the terminal illness and in normal spleens from the nontransgenic littermates. These results suggest that PRAK suppresses JNK activity in hematopoietic tumor cells as well as in normal hematopoietic cells. The promitogenic and prooncogenic role of the JNK pathway has been well established in multiple cell types including lymphoma cells (6, (25) (26) (27) . Indeed, we found that JNK activation correlates with enhanced proliferation of hematopoietic cells in vivo and in vitro, as revealed by a higher number of Ki-67-positive cells in spleens and an increased proliferation rate in splenocytes, respectively, and that PRAK deficiency promotes oncogenic ras-induced soft agar colony formation in a JNK-dependent manner. These findings suggest that hyperactivation of the JNK pathway plays a key role in the acceleration of hematopoietic cancer development by PRAK deletion. Supporting this notion, several articles have reported that p38 arrests cell proliferation and suppresses tumorigenesis by antagonizing the JNK pathway (6, 28) . (N-Ras), or vector control (VT) and plated in triplicates onto 6-well plates at a density of 1 Â 10 4 cells per well in NIH3T3-conditioned splenocyte medium containing 0.3% low melting point agarose. Inset, Western blot analysis showing knockdown of JNK1 and JNK2 by shRNA (S1 and S2) as compared with the control shRNA (Ctrl). B and C, cells were stained with 0.02% Giemsa in PBS 3 weeks later, and numbers of colonies were quantified using the AlphaView Software (Cell Biosciences). Numbers are mean AE SD for triplicates. Statistical significance was determined by Student t test. Ã , P < 0.005; ÃÃ , P < 0.01 for Ras-SP600125 versus Ras-DMSO or Ras-shJNK versus Ras-Ctrl. D, cell numbers were counted 4 days after 2 Â 10 4 of Em-N-Ras
G12D
;PRAK Interestingly, despite the general mitogenic activity of JNKs shown by multiple studies, it was found that JNK1 negatively regulates T-cell receptor-initiated proliferation of CD4 helper (T H ) cells (29) , suggesting that the function of this pathway may differ in response to distinct stimuli such as oncogenic signals and T-cell receptor activation.
In the previous study, we found that PRAK suppresses skin carcinogenesis by mediating oncogene-induced senescence (17) . PRAK-mediated senescence may also, at least partially, contribute to the suppression of hematopoietic tumorigenesis. Although we failed to observe growth arrest in hematopoietic cells transduced with oncogenic ras, at least a subset of senescence markers were induced in a PRAKdependent manner. Although we do not understand the precise reason why activated ras fails to induce growth arrest despite the obvious PRAK-dependent induction of some senescence markers, it is possible that induction of senescence occurs only in a subpopulation of cells, whereas the remaining cells acquire a higher proliferation rate due to the moderate activation of JNK by oncogenic ras alone. As a result, the growth arrest in this subpopulation of senescent cells may have been obscured by the increased proliferation of the other cells in the growth curve assay, even though the more sensitive Western blot analysis detected alterations in senescence markers. It remains to be determined whether hyperactivation of JNK in PRAK-deficient hematopoietic cells leads to disruption of ras-induced senescence or rasinduced accumulation of senescence markers. However, the fact that activated ras alone causes moderate JNK activation and increased levels of senescence markers at the same time argues against a role of JNK activation in senescence bypass. Taken together with the well-established role of JNK in promoting cell proliferation, our data are consistent with the notion that JNK hyperactivation by PRAK deficiency contributes to accelerated tumorigenesis by enhancing cell proliferation, rather than by disrupting senescence, in hematopoietic compartments. On the other hand, PRAKmediated senescence may only occur in a small subpopulation of hematopoietic cells and thus is unlikely to be the major mechanism underlying the tumor-suppressing function of PRAK in this system. Several recent articles reported hematopoietic malignancies in mice expressing oncogenic N-ras G12D from the endogenous locus (30) (31) (32) . In these mice, a loxP-STOPloxP (LSL)-N-ras G12D allele was knocked into the N-ras locus, and its expression was induced specifically in hematopoietic cells by Mx1-Cre. The Mx1-Cre, LSL-Nras G12D mice initially developed an indolent myeloproliferative disorder ;PRAK þ/þ and Em-N-Ras G12D ;PRAK À/À littermates (C, bottom right).
